{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:35:07Z","timestamp":1760056507779,"version":"build-2065373602"},"reference-count":71,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiology Clinics"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ccl.2023.06.007","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T07:05:24Z","timestamp":1695366324000},"page":"511-524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sequencing Quadruple Therapy for Heart Failure with Reduced Ejection Fraction: Does It Really Matter?"],"prefix":"10.1016","volume":"41","author":[{"given":"Jiun-Ruey","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra N.","family":"Schwann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia Wei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulelah","family":"Nuqali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph J.","family":"Riello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael H.","family":"Beasley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10166","key":"10.1016\/j.ccl.2023.06.007_bib1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(18)32484-X","article-title":"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial","volume":"393","author":"Halliday","year":"2019","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.ccl.2023.06.007_bib2","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American heart association joint Committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccl.2023.06.007_bib3","unstructured":"Tan J, Hu JR. GDMT for Everyone. Guideline-Directed Medical Therapy for Everyone. Published May 2022. Available at: www.GDMT.org. Accessed January 31, 2023."},{"key":"10.1016\/j.ccl.2023.06.007_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.ccl.2023.06.007_bib5","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American heart association joint Committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ccl.2023.06.007_bib6","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin\u2013neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.ccl.2023.06.007_bib7","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.jacc.2003.12.040","volume":"43","author":"Gattis","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"13","key":"10.1016\/j.ccl.2023.06.007_bib8","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/archinte.164.13.1389","article-title":"Adverse effects of \u03b2-blocker therapy for patients with heart failure: a quantitative overview of randomized trials","volume":"164","author":"Ko","year":"2004","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1016\/j.ccl.2023.06.007_bib9","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF Registry","volume":"72","author":"Greene","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"17","key":"10.1016\/j.ccl.2023.06.007_bib10","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jacc.2013.04.086","article-title":"Safety and efficacy of Eplerenone in patients at high risk for hyperkalemia and\/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild patients hospitalization and SurvIval study in heart failure)","volume":"62","author":"Eschalier","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.ccl.2023.06.007_bib11","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.amjcard.2014.05.062","article-title":"Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH study)","volume":"114","author":"Maisel","year":"2014","journal-title":"Am J Cardiol"},{"issue":"9","key":"10.1016\/j.ccl.2023.06.007_bib12","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1001\/jamacardio.2017.2198","article-title":"Efficacy and safety of spironolactone in acute heart failure: the ATHENA-HF randomized clinical trial","volume":"2","author":"Butler","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"41","key":"10.1016\/j.ccl.2023.06.007_bib13","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","article-title":"Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ccl.2023.06.007_bib14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2217\/fca.11.71","article-title":"PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016","volume":"8","author":"Buysse","year":"2012","journal-title":"Future Cardiol"},{"key":"10.1016\/j.ccl.2023.06.007_bib15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ahj.2017.03.011","article-title":"True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: a meta-analysis","volume":"188","author":"Vukadinovi\u0107","year":"2017","journal-title":"Am Heart J"},{"issue":"4","key":"10.1016\/j.ccl.2023.06.007_bib16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/clc.20324","article-title":"A\u00a0comparison of the aldosterone-blocking agents Eplerenone and spironolactone","volume":"31","author":"Struthers","year":"2008","journal-title":"Clin Cardiol"},{"issue":"3","key":"10.1016\/j.ccl.2023.06.007_bib17","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"issue":"10254","key":"10.1016\/j.ccl.2023.06.007_bib18","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet Lond Engl"},{"issue":"9","key":"10.1016\/j.ccl.2023.06.007_bib19","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1002\/ejhf.2301","article-title":"Another reason to embrace quadruple medical therapy for heart failure: medications enabling tolerance of each other","volume":"23","author":"Greene","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"10.1016\/j.ccl.2023.06.007_bib20","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1111\/dom.13820","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: a population-based study of older women and men with diabetes","volume":"21","author":"Lega","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.ccl.2023.06.007_bib21","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/CIRCULATIONAHA.120.052926","article-title":"How should we sequence the treatments for heart failure and a reduced ejection fraction?","volume":"143","author":"McMurray","year":"2021","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.ccl.2023.06.007_bib22","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jchf.2022.10.005","article-title":"How to initiate and uptitrate GDMT in heart failure: practical stepwise approach to optimization of GDMT","volume":"10","author":"Bozkurt","year":"2022","journal-title":"JACC Heart Fail"},{"issue":"7","key":"10.1016\/j.ccl.2023.06.007_bib23","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jamacardio.2021.0496","article-title":"Simultaneous or rapid sequence initiation of quadruple medical therapy for heart failure\u2014optimizing therapy with the need for speed","volume":"6","author":"Greene","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"11","key":"10.1016\/j.ccl.2023.06.007_bib24","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in heart failure","volume":"142","author":"Griffin","year":"2020","journal-title":"Circulation"},{"issue":"36","key":"10.1016\/j.ccl.2023.06.007_bib25","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1093\/eurheartj\/ehaa496","article-title":"Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)","volume":"41","author":"Serenelli","year":"2020","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.ccl.2023.06.007_bib26","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jchf.2019.09.011","article-title":"Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction","volume":"8","author":"Serenelli","year":"2020","journal-title":"Jacc Heart Fail"},{"issue":"9","key":"10.1016\/j.ccl.2023.06.007_bib27","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1001\/jamacardio.2017.2198","article-title":"Efficacy and safety of spironolactone in acute heart failure","volume":"2","author":"Butler","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"2","key":"10.1016\/j.ccl.2023.06.007_bib28","doi-asserted-by":"crossref","first-page":"e007034","DOI":"10.1161\/CIRCHEARTFAILURE.120.007034","article-title":"Efficacy and safety of sacubitril\/valsartan in high-risk patients in the PIONEER-HF trial","volume":"14","author":"Berg","year":"2021","journal-title":"Circ Heart Fail"},{"issue":"4","key":"10.1016\/j.ccl.2023.06.007_bib29","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000093060","article-title":"Comparing beta-blocking effects of bisoprolol, carvedilol and nebivolol","volume":"106","author":"Stoschitzky","year":"2006","journal-title":"Cardiology"},{"issue":"3","key":"10.1016\/j.ccl.2023.06.007_bib30","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1388-9842(01)00126-X","article-title":"Differing beta-blocking effects of carvedilol and metoprolol","volume":"3","author":"Stoschitzky","year":"2001","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"10.1016\/j.ccl.2023.06.007_bib31","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/S0735-1097(99)00367-8","article-title":"Beta-blockade in heart failure: a comparison of carvedilol with metoprolol","volume":"34","author":"Sanderson","year":"1999","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.ccl.2023.06.007_bib32","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.jacc.2003.11.037","article-title":"Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study","volume":"43","author":"Rouleau","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.ccl.2023.06.007_bib33","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1161\/CIRCHEARTFAILURE.112.972240","article-title":"Response to Ryan and Parwani: heart failure patients with low blood pressure: How should we manage neurohormonal blocking drugs?","volume":"5","author":"Bozkurt","year":"2012","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10.1016\/j.ccl.2023.06.007_bib34","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cardfail.2021.08.008","article-title":"Treatment persistence of renin-angiotensin-aldosterone-system inhibitors over time in heart failure with reduced ejection fraction","volume":"28","author":"Vaduganathan","year":"2022","journal-title":"J\u00a0Card Fail"},{"issue":"15","key":"10.1016\/j.ccl.2023.06.007_bib35","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ccl.2023.06.007_bib36","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.ccl.2023.06.007_bib37","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.ccl.2023.06.007_bib38","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.ccl.2023.06.007_bib39","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1681\/ASN.2021020167","article-title":"Effects of dapagliflozin in stage 4 chronic kidney disease","volume":"32","author":"Chertow","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.ccl.2023.06.007_bib40","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.kint.2022.06.013","article-title":"Executive summary of the KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease: an update based on rapidly emerging new evidence","volume":"102","author":"Rossing","year":"2022","journal-title":"Kidney Int"},{"issue":"11","key":"10.1016\/j.ccl.2023.06.007_bib41","doi-asserted-by":"crossref","first-page":"e007180","DOI":"10.1161\/CIRCHEARTFAILURE.120.007180","article-title":"Association between \u03b2-blocker use and mortality\/morbidity in patients with heart failure with reduced, midrange, and preserved ejection fraction and advanced chronic kidney disease","volume":"13","author":"Fu","year":"2020","journal-title":"Circ Heart Fail"},{"issue":"8","key":"10.1016\/j.ccl.2023.06.007_bib42","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.cardfail.2017.04.014","volume":"23","author":"Yancy","year":"2017","journal-title":"J\u00a0Card Fail"},{"issue":"3","key":"10.1016\/j.ccl.2023.06.007_bib43","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"Suppl","year":"2013","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.ccl.2023.06.007_bib44","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jchf.2022.08.001","article-title":"The need to stop Inappropriate Coding for acute kidney injury in heart failure","volume":"10","author":"Bozkurt","year":"2022","journal-title":"JACC Heart Fail"},{"issue":"5","key":"10.1016\/j.ccl.2023.06.007_bib45","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.kint.2019.05.019","article-title":"Acute declines in estimated glomerular filtration rate on enalapril and mortality and cardiovascular outcomes in patients with heart failure with reduced ejection fraction","volume":"96","author":"McCallum","year":"2019","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.ccl.2023.06.007_bib46","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.kint.2020.10.031","article-title":"Characterization and implications of the initial estimated glomerular filtration rate \u2018dip\u2019 upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial","volume":"99","author":"Kraus","year":"2021","journal-title":"Kidney Int"},{"issue":"10","key":"10.1016\/j.ccl.2023.06.007_bib47","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.amjcard.2012.01.367","article-title":"Predictors of hyperkalemia and death in patients with cardiac and renal disease","volume":"109","author":"Jain","year":"2012","journal-title":"Am J Cardiol"},{"issue":"10","key":"10.1016\/j.ccl.2023.06.007_bib48","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"issue":"48","key":"10.1016\/j.ccl.2023.06.007_bib49","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1093\/eurheartj\/ehab497","article-title":"Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial","volume":"42","author":"Neuen","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ccl.2023.06.007_bib50","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1161\/CIRCHEARTFAILURE.109.932558","article-title":"Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease","volume":"4","author":"Wali","year":"2011","journal-title":"Circ Heart Fail"},{"issue":"9054","key":"10.1016\/j.ccl.2023.06.007_bib51","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(97)01187-2","article-title":"Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)","volume":"349","author":"Pitt","year":"1997","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ccl.2023.06.007_bib52","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","article-title":"Comparison of Candesartan, enalapril, and their Combination in Congestive heart failure","volume":"100","author":"McKelvie","year":"1999","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ccl.2023.06.007_bib53","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1411487","article-title":"Sodium zirconium cyclosilicate in hyperkalemia","volume":"372","author":"Packham","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccl.2023.06.007_bib54","unstructured":"Lokelma\u00ae (sodium zirconium cyclosilicate) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2022."},{"issue":"3","key":"10.1016\/j.ccl.2023.06.007_bib55","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.ccl.2023.06.007_bib56","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","article-title":"Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial","volume":"32","author":"Pitt","year":"2011","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.ccl.2023.06.007_bib57","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jchf.2021.09.004","article-title":"A\u00a0systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction","volume":"10","author":"Tromp","year":"2022","journal-title":"JACC Heart Fail"},{"issue":"41","key":"10.1016\/j.ccl.2023.06.007_bib58","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.1093\/eurheartj\/ehac399","article-title":"Potassium binders for patients with heart failure? The real enlightenment of the DIAMOND trial","volume":"43","author":"Packer","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ccl.2023.06.007_bib59","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jamacardio.2016.4733","article-title":"Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril\/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trial","volume":"2","author":"Desai","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"31","key":"10.1016\/j.ccl.2023.06.007_bib60","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1093\/eurheartj\/ehac306","article-title":"Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled","volume":"43","author":"Ferreira","year":"2022","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.ccl.2023.06.007_bib61","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.hroo.2021.11.006","article-title":"Atrial fibrillation and heart failure: a contemporary review of current management approaches","volume":"2","author":"Lee","year":"2021","journal-title":"Heart Rhythm O2"},{"issue":"3","key":"10.1016\/j.ccl.2023.06.007_bib62","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/ejhf.1682","article-title":"Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction","volume":"22","author":"Docherty","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10.1016\/j.ccl.2023.06.007_bib63","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/ejhf.1733","article-title":"Heart rate control in heart failure with reduced ejection fraction: the bright and the dark side of the moon","volume":"22","author":"Bauersachs","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.ccl.2023.06.007_bib64","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"Eur Heart J"},{"issue":"9961","key":"10.1016\/j.ccl.2023.06.007_bib65","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0140-6736(14)61373-8","article-title":"Efficacy of \u03b2 blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis","volume":"384","author":"Kotecha","year":"2014","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.ccl.2023.06.007_bib66","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1161\/CIRCULATIONAHA.115.019406","article-title":"Ablation versus Amiodarone for treatment of persistent atrial fibrillation in patients with Congestive heart failure and an implanted device","volume":"133","author":"Di Biase","year":"2016","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ccl.2023.06.007_bib67","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1707855","article-title":"Catheter ablation for atrial fibrillation with heart failure","volume":"378","author":"Marrouche","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"46","key":"10.1016\/j.ccl.2023.06.007_bib68","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1093\/eurheartj\/ehab569","article-title":"AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial","volume":"42","author":"Brignole","year":"2021","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.ccl.2023.06.007_bib69","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1161\/01.CIR.94.11.2807","article-title":"Carvedilol produces dose-related improvements in Left ventricular function and survival in Subjects with chronic heart failure","volume":"94","author":"Bristow","year":"1996","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ccl.2023.06.007_bib70","first-page":"69","article-title":"Different effects of propranolol, bisoprolol, carvedilol and doxazosin on heart rate, blood pressure, and plasma concentrations of epinephrine and norepinephrine","volume":"6","author":"Stoschitzky","year":"2003","journal-title":"J\u00a0Clin Basic Cardiol"},{"issue":"1","key":"10.1016\/j.ccl.2023.06.007_bib71","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/1074248407312629","article-title":"Differential effects of carvedilol and metoprolol succinate on plasma norepinephrine release and peak exercise heart rate in Subjects with chronic heart failure","volume":"13","author":"Vittorio","year":"2008","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"}],"container-title":["Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865123000632?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865123000632?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:55:36Z","timestamp":1760007336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733865123000632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":71,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0733865123000632"],"URL":"https:\/\/doi.org\/10.1016\/j.ccl.2023.06.007","relation":{},"ISSN":["0733-8651"],"issn-type":[{"type":"print","value":"0733-8651"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sequencing Quadruple Therapy for Heart Failure with Reduced Ejection Fraction: Does It Really Matter?","name":"articletitle","label":"Article Title"},{"value":"Cardiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccl.2023.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}